Nuclear Factor kappa B in the Treatment of Inflammatory and Tumor Diseases
Authors:
M. Xeníček; L. '• 'muchová; L. L' 'vítek
Authors‘ workplace:
Ústav klinické biochemie a laboratorní diagnostiky 1. LF UK a VFN, Praha 2 IV. interní klinika 1. LF UK a VFN, Praha
Published in:
Čas. Lék. čes. 2004; : 680-684
Category:
Overview
Since its discovery in 1986 nuclear factor kappa B attracted attention of scientists all over the world. Intensiveresearch has proved its indisputable role in pathogenesis of particularly inflammatory and tumor diseases and revealedmany possibilities in the modulation of its function. For some of the modulators distinct therapeutic effects hávebeen proved in in vitro and in vivo studies oř even in the clinical trials, some of them are still to be tested. One mayexpect wide use of different inhibitors oř modulators of nuclear factor kappa B in various indications, which willmarkedly enhance the therapeutic effect
Key words:
apoptosis, nuclear factor kappa B, tumorigenesis, tumors, therapy, inflammation.
Labels
Addictology Allergology and clinical immunology Angiology Audiology Clinical biochemistry Dermatology & STDs Paediatric gastroenterology Paediatric surgery Paediatric cardiology Paediatric neurology Paediatric ENT Paediatric psychiatry Paediatric rheumatology Diabetology Pharmacy Vascular surgery Pain management Dental HygienistArticle was published in
Journal of Czech Physicians
Most read in this issue
- Regression of Atherosclerotic Plaques during Treatment with Statins
- Čase Reports ofPatients with a Marker Chromosome
- A Severe Čase with Respiratory Insufficiency
- Evaluation ofthe Clinical Effectivity and Toxicity ofthe FDN Regimen (Fludarabin, Mitoxantron, Dexamethason) in Patients with FoUicular Lymphoma